Abstract
Wastewater based epidemiology (WBE) has drawn significant attention as an early warning tool to detect and predict the trajectory of COVID-19 cases in a community, in conjunction with public health data. This means of monitoring for outbreaks has been used at municipal wastewater treatment centers to analyze COVID-19 trends in entire communities, as well as by universities and other community living environments to monitor COVID-19 spread in buildings. Sample concentration is crucial, especially when viral abundance in raw wastewater is below the threshold of detection by RT-qPCR analysis. We evaluated the performance of a rapid ultrafiltration-based virus concentration method using InnovaPrep Cp Select pipette tips and compared this to the established electronegative membrane filtration (EMF) method. We evaluated sensitivity of SARS-CoV-2 quantification, surrogate virus recovery rate, and sample processing time. Results suggest that the Cp Select concentrator is more efficient at concentrating SARS-CoV-2 from wastewater compared to the EMF method. 30% of samples that tested negative when concentrated with the EMF method produced a positive signal with the Cp Select protocol. Increased recovery of the surrogate virus control using the Cp Select confirms this observation. We optimized the Cp Select protocol by adding AVL lysis buffer and sonication, to increase the recovery of virus. Sonication increased BCoV recovery by 19%, which seems to compensate for viral loss during centrifugation. Filtration time decreases by approximately 30% when using the Cp Select protocol, making this an optimal choice for building surveillance applications where quick turnaround time is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the University of North Carolina Charlotte, Office of Research and Economic Development.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UNCC Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is provided in the supplementary file and also available from the authors upon request.
